Search

Your search keyword '"Odorici, Giulia"' showing total 179 results
Start Over Author "Odorici, Giulia"
179 results on '"Odorici, Giulia"'

1. Lichen Planus

Author

Borghi, Alessandro, primary, Toni, Giulia, additional, Odorici, Giulia, additional, Gafà, Roberta, additional, and Corazza, Monica, additional

Published
2021
Full Text
View/download PDF

5. Darier’s Disease

Author

Bardazzi, Federico, Odorici, Giulia, Balestri, Riccardo, Katsambas, Andreas D., editor, Lotti, Torello M., editor, Dessinioti, Clio, editor, and D’Erme, Angelo Massimiliano, editor

Published
2015
Full Text
View/download PDF

6. Dimethyl Fumarate Treatment in Patients with Moderate-to-Severe Psoriasis: A 52-week Real-life Study

Author

Gnesotto, Laura, primary, Mioso, Guido, additional, Bardazzi, Federico, additional, Filippi, Federica, additional, Di Lernia, Vito, additional, Motolese, Alberico, additional, Di Nuzzo, Sergio, additional, Conti, Andrea, additional, Arginelli, Federica, additional, Corazza, Monica, additional, Odorici, Giulia, additional, Borghi, Alessandro, additional, Gisondi, Paolo, additional, Naldi, Luigi, additional, Dapavo, Paolo, additional, Parodi, Aurora, additional, Burlando, Martina, additional, and Piaserico, Stefano, additional

Published
2023
Full Text
View/download PDF

12. Long-term proactive management of psoriasis with calcipotriol and betamethasone dipropionate foam: an Italian consensus through a combined nominal group technique and Delphi approach

Author

De Simone, Clara, Dapavo, Paolo, Malagoli, Piergiorgio, Martella, Alessandro, Campanati, Anna, Campione, Elena, Errichetti, Enzo, Franchi, Chiara, Gambardella, Alessio, Megna, Matteo, Osti, Federica, Ribero, Simone, Zagni, Giovanni, Calzavara-Pinton, Piergiacomo, Fabbrocini, Gabriella, Amoruso, Giuseppe Fabrizio, Baglieri, Francesco, Biamonte, Anna Silvia, Bianchelli, Tommaso, Bigi, Laura, Bortoli, Jarno, Brunetti, Bruno, Buligan, Cinzia, Cagni, Elisabetta, Calderoni, Ombretta, Caputo, Alighiero, Carrera, Carlo Giovanni, Carugno, Andrea, Chersi, Karin, Cicchelli, Stefano, De Natale, Flora, Di Maria, Domenico, Ferrari, Angelo Salvatore, Fogli, Emanuela, Forconi, Riccardo, Galeazzi, Augusto, Giovannini, Andrea, Giura, Maria Teresa, Iuculano, Massimo, Lazzaretti, Giuseppe, Leporati, Claudia, Magnanini, Massimiliano, Marconi, Barbara, Maruccia, Adriana, Miglietta, Roberta, Minuti, Anna, Mocci, Luigi, Modica, Sonia, Narcisi, Alessandra, Odorici, Giulia, Pazzaglia, Massimiliano, Peila, Rossana, Pertusi, Ginevra, Pezza, Michele, Pezzullo, Elio, Puccia, Nunzio, Raulo, Umberto, Rossi, Mariateresa, Rusignuolo, Sergio, Sapienza, Giada, Savarese, Catello, Scalisi, Mariaelena, Strippoli, Davide, Stroppiana, Elena, Tiberio, Rossana, Trischitta, Antonino, Tucci, Maria Giovanna, Vaira, Fabrizio, Verrone, Anna, Villa, Lucia, Zagni, Fabio, Zoccali, Andrea, De Simone, C, Dapavo, P, Malagoli, P, Martella, A, Campanati, A, Campione, E, Errichetti, E, Franchi, C, Gambardella, A, Megna, M, Osti, F, Ribero, S, Zagni, G, Calzavara-Pinton, P, Fabbrocini, G, Amoruso, G, Baglieri, F, Biamonte, A, Bianchelli, T, Bigi, L, Bortoli, J, Brunetti, B, Buligan, C, Cagni, E, Calderoni, O, Caputo, A, Carrera, C, Carugno, A, Chersi, K, Cicchelli, S, De Natale, F, Di Maria, D, Ferrari, A, Fogli, E, Forconi, R, Galeazzi, A, Giovannini, A, Giura, M, Iuculano, M, Lazzaretti, G, Leporati, C, Magnanini, M, Marconi, B, Maruccia, A, Miglietta, R, Minuti, A, Mocci, L, Modica, S, Narcisi, A, Odorici, G, Pazzaglia, M, Peila, R, Pertusi, G, Pezza, M, Pezzullo, E, Puccia, N, Raulo, U, Rossi, M, Rusignuolo, S, Sapienza, G, Savarese, C, Scalisi, M, Strippoli, D, Stroppiana, E, Tiberio, R, Trischitta, A, Tucci, M, Vaira, F, Verrone, A, Villa, L, Zagni, F, Zoccali, A, De Simone, Clara, Dapavo, Paolo, Malagoli, Piergiorgio, Martella, Alessandro, Campanati, Anna, Campione, Elena, Errichetti, Enzo, Franchi, Chiara, Gambardella, Alessio, Megna, Matteo, Osti, Federica, Ribero, Simone, Zagni, Giovanni, Calzavara-Pinton, Piergiacomo, Fabbrocini, Gabriella, Amoruso, Giuseppe Fabrizio, Baglieri, Francesco, Biamonte, Anna Silvia, Bianchelli, Tommaso, Bigi, Laura, Bortoli, Jarno, Brunetti, Bruno, Buligan, Cinzia, Cagni, Elisabetta, Calderoni, Ombretta, Caputo, Alighiero, Carrera, Carlo Giovanni, Carugno, Andrea, Chersi, Karin, Cicchelli, Stefano, De Natale, Flora, Di Maria, Domenico, Ferrari, Angelo Salvatore, Fogli, Emanuela, Forconi, Riccardo, Galeazzi, Augusto, Giovannini, Andrea, Giura, Maria Teresa, Iuculano, Massimo, Lazzaretti, Giuseppe, Leporati, Claudia, Magnanini, Massimiliano, Marconi, Barbara, Maruccia, Adriana, Miglietta, Roberta, Minuti, Anna, Mocci, Luigi, Modica, Sonia, Narcisi, Alessandra, Odorici, Giulia, Pazzaglia, Massimiliano, Peila, Rossana, Pertusi, Ginevra, Pezza, Michele, Pezzullo, Elio, Puccia, Nunzio, Raulo, Umberto, Rossi, Mariateresa, Rusignuolo, Sergio, Sapienza, Giada, Savarese, Catello, Scalisi, Mariaelena, Strippoli, Davide, Stroppiana, Elena, Tiberio, Rossana, Trischitta, Antonino, Tucci, Maria Giovanna, Vaira, Fabrizio, Verrone, Anna, Villa, Lucia, Zagni, Fabio, and Zoccali, Andrea

Subjects
Aerosols, long-term, proactive management, Dermatology, psoriasis, Betamethasone, Drug Combinations, Treatment Outcome, Recurrence, consensus, Cal/BD, adherence, consensu, Humans, Dermatologic Agents, psoriasi
Abstract

Background: Although long-term management of psoriasis is paramount, this approach is challenging in clinical practice. In the recent PSO-LONG trial, a fixed-dose combination of betamethasone dipropionate (BD) and calcipotriol (Cal) foam applied twice a week on non-consecutive days for 52 weeks (proactive treatment) reduced the risk of relapse. However, the role of Cal/BD foam in the long-term management of psoriasis needs further clarifications. The ProActive Management (PAM) program, a nationwide Italian project, aims at reaching a consensus on the role of proactive management of psoriasis. Methods: A steering committee generated some statements through the nominal group technique (NGT). The statements were voted by an expert panel in an adapted Delphi voting process. Results: Eighteen statements were proposed, and the majority of them (14/18) reached a consensus during the Delphi voting. The need to provide long-term proactive topical treatment to reduce the risk of relapse for the treatment of challenging diseases sites or in patients where phototherapy or systemic therapies are contraindicated/ineffective was widely recognized. A consensus was reached about the possibility to associate the proactive treatment with systemic and biological therapies, without the need for dose intensification, thus favoring a prolonged remission. Moreover, the proactive treatment was recognized as more effective than weekend therapy in increasing time free from relapses. Approaches to improve adherence, on the other hand, need further investigation. Conclusions: The inclusion in guidelines of a proactive strategy among the effective treatment options will be a fundamental step in the evolution of a mild-moderate psoriasis therapeutic approach.

Published
2022

13. Use of Apremilast® in the psoriasis treatment: a real-life multicenter Italian experience

Author

FILIPPI, Federica, primary, PATRIZI, Annalisa, additional, IEZZI, Luca, additional, CARPANESE, Miriam A., additional, CONTI, Andrea, additional, LASAGNI, Claudia, additional, TABANELLI, Michela, additional, D’ADAMIO, Simone, additional, DI NUZZO, Sergio, additional, CORTELAZZI, Chiara, additional, DI LERNIA, Vito, additional, PECCERILLO, Francesca, additional, CORAZZA, Monica, additional, ODORICI, Giulia, additional, and BARDAZZI, Federico, additional

Published
2022
Full Text
View/download PDF

15. Secukinumab Loss of Efficacy Is Perfectly Counteracted by the Introduction of Combination Therapy (Rescue Therapy): Data from a Multicenter Real-Life Study in a Cohort of Italian Psoriatic Patients That Avoided Secukinumab Switching

Author

Damiani, Giovanni, primary, Odorici, Giulia, additional, Pacifico, Alessia, additional, Morrone, Aldo, additional, Conic, Rosalynn R. Z., additional, Davidson, Tima, additional, Watad, Abdulla, additional, Pigatto, Paolo D. M., additional, Colombo, Delia, additional, Malagoli, Piergiorgio, additional, and Fiore, Marco, additional

Published
2022
Full Text
View/download PDF

22. Dimethyl fumarate treatment for psoriasis in a real‐life setting: A multicentric retrospective study

Author

Corazza, Monica, primary, Odorici, Giulia, additional, Conti, Andrea, additional, Di Lernia, Vito, additional, Motolese, Alberico, additional, Bardazzi, Federico, additional, Di Nuzzo, Sergio, additional, Monti, Alberto, additional, Arginelli, Federica, additional, Filippi, Federica, additional, Valpiani, Giorgia, additional, Morotti, Chiara, additional, and Borghi, Alessandro, additional

Published
2021
Full Text
View/download PDF

25. Seven years-experience of adalimumab therapy for Hidradenitis Suppurativa in a real-life dermatologic setting.

Author

Odorici, Giulia, Pacetti, Lucrezia, Forconi, Riccardo, Schettini, Natale, Zedde, Pierantonia, Corazza, Monica, and Bettoli, Vincenzo

Subjects
*HIDRADENITIS suppurativa, *ADALIMUMAB, *BIOTHERAPY, *TREATMENT duration, *OUTPATIENT medical care
Abstract

Hidradenitis Suppurativa (HS) often causes severe impairment of the quality of life of patients affected, as it is characterized by recurrent relapses of inflammation and predisposes to retractive scars, with severe alteration of anatomy of the affected regions. Adalimumab is currently the only approved long-term biological therapy for this disease. We retrospectively review the data of HS patients treated with Adalimumab at the 'Hidradenitis Suppurativa Clinic', University of Ferrara, Italy since the drug was first available to October 2020. The aim is to describe our real-life experience in a clinical outpatient service. We assessed the main demographic features, therapy duration, reasons of suspension and efficacy (evaluated by HiSCR – Hidradenitis Score) in relation to surgical procedures, hospitalization, number of areas involved by the disease and BMI > 30. We also assessed the aspects related to the use of adalimumab's biosimilar. Data on 76 patients, with a mean age of 38.26 ± 14.74 years and mean BMI 28.10 ± 5.92 were collected. Most of the treated patients had Hurley stage III (58/76); mean Sartorius score was 115.5 ± 55.86, mean IHS4 was 76.1 ± 44.3. A statistically significant correlation between hospitalization and cessation of adalimumab, the loss of the achievement of the HiSCR, and surgery was found. No need to do surgery was a protective factor against the failure of adalimumab treatment, meaning that the most severe cases are more likely to fail the biological therapy. New scenarios are opening up in clinical practice: the arrival of biosimilars allow greater sustainability of expenditure, while the anti-IL17 allow the patient who has failed therapy with adalimumab a valid and safe therapeutic option to be undertaken. A comprehensive care including hospitalization, a specific antibiotic therapy and surgical treatment is often mandatory to achieve a satisfactory control of the disease. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

31. Phototherapy: The patients' point of view

Author

Odorici, Giulia, primary, Di Nuzzo, Sergio, additional, Corazza, Monica, additional, Bardazzi, Federico, additional, Cortelazzi, Chiara, additional, Sacchelli, Lidia, additional, and Conti, Andrea, additional

Published
2020
Full Text
View/download PDF

34. Cutaneous squamous cell carcinoma in patients with chronic lymphocytic leukemia: a systematic review of the literature.

Author

Lai, Michela, Pampena, Riccardo, Cornacchia, Luigi, Odorici, Giulia, Piccerillo, Alfredo, Pellacani, Giovanni, Peris, Ketty, and Longo, Caterina

Subjects
CHRONIC lymphocytic leukemia, SQUAMOUS cell carcinoma, SECONDARY primary cancer, TRANSPLANTATION of organs, tissues, etc.
Abstract

The continuous improvement of life expectancy of patients with chronic lymphocytic leukemia (CLL) has resulted in increased risk of second primary malignancy that potentially may affect survival and quality of life of CLL patients. We performed a systematic review to assess the risk and the clinical‐pathological features and prognosis of cutaneous squamous cell carcinoma (cSCC) in patients with CLL. We searched PubMed, Embase, and Cochrane Central Register of Control Trials databases for articles published from database inception to December 31, 2019. English‐language studies reporting original data on patients with a specific diagnosis of CLL and cSCC were included. Data were extracted using a standardized extraction form, and any discordance was resolved by consensus. Descriptive data were generated by pooling patients from eligible studies. Of the 4588 non‐duplicate records identified, 55 articles met our inclusion criteria. These studies reported that CLL patients have a 3.2% prevalence of cSCC, with an 11.5% cSCC‐related lethality and an overall risk of metastasis of 5.7% (7.3% for regional lymph node involvement and 3.8% for distant metastasis). The quality of evidence was limited by the high heterogeneity in the design, populations, and objectives of the included studies. This systematic review suggests that cSCC in CLL patients tends to behave less aggressively compared with the solid organ transplant recipients but has a higher morbidity and mortality than in the general population. Future prospective studies are needed to increase the quality of evidence and to determine the best treatment modalities and screening intervals for these patients. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

36. Measuring perceived benefit and disease‐related burden in patients affected with vulvar lichen sclerosus after a standard topical corticosteroid treatment. Results from a cohort study using Pictorial Representation of Illness and Self‐measure and Dermatology Life Quality Index

Author

Borghi, Alessandro, primary, Odorici, Giulia, additional, Scuderi, Valeria, additional, Valpiani, Giorgia, additional, Morotti, Chiara, additional, and Corazza, Monica, additional

Published
2020
Full Text
View/download PDF

37. Patients’ demographic and socioeconomic characteristics influence the therapeutic decision-making process in psoriasis

Author

Scala, Emanuele, primary, Megna, Matteo, additional, Amerio, Paolo, additional, Argenziano, Giuseppe, additional, Babino, Graziella, additional, Bardazzi, Federico, additional, Bianchi, Luca, additional, Caldarola, Giacomo, additional, Campanati, Anna, additional, Cannavò, Serafinella Patrizia, additional, Chiricozzi, Andrea, additional, Conti, Andrea, additional, Damiani, Giovanni, additional, Dapavo, Paolo, additional, De Simone, Clara, additional, Esposito, Maria, additional, Fabbrocini, Gabriella, additional, Fargnoli, Maria Concetta, additional, Ferrara, Francesca, additional, Fidanza, Rosaria, additional, Gualdi, Giulio, additional, Guarneri, Claudio, additional, Hansel, Katharina, additional, Malagoli, Piergiorgio, additional, Malara, Giovanna, additional, Micali, Giuseppe, additional, Mugheddu, Cristina, additional, Musumeci, Maria Letizia, additional, Odorici, Giulia, additional, Offidani, Annamaria, additional, Pescitelli, Leonardo, additional, Prignano, Francesca, additional, Raimondo, Annunziata, additional, Ribero, Simone, additional, Rongioletti, Franco, additional, Stingeni, Luca, additional, Trifirò, Caterina, additional, Zanframundo, Salvatore, additional, and Balato, Anna, additional

Published
2020
Full Text
View/download PDF

41. Chronic kidney disease in psoriasis: a cohort study

Author

Conti, Andrea, primary, Giovannini, Lisa, additional, Mandel, Victor Desmond, additional, Odorici, Giulia, additional, Lasagni, Claudia, additional, Bigi, Laura, additional, Pellacani, Giovanni, additional, and Cappelli, Gianni, additional

Published
2020
Full Text
View/download PDF

42. Switching from Secukinumab to Ustekinumab in Psoriasis Patients: Results from a Multicenter Experience

Author

Chiricozzi, Andrea, Conti, Andrea, Burlando, Martina, Odorici, Giulia, Gaiani, Francesca, Panduri, Salvatore, Malagoli, Piergiorgio, Chiricozzi, Andrea (ORCID:0000-0002-6739-0387), Chiricozzi, Andrea, Conti, Andrea, Burlando, Martina, Odorici, Giulia, Gaiani, Francesca, Panduri, Salvatore, Malagoli, Piergiorgio, and Chiricozzi, Andrea (ORCID:0000-0002-6739-0387)

Abstract

BACKGROUND: Switching between biologics is commonly performed for the management of plaque psoriasis. However, no evidence about switching from secukinumab to ustekinumab has been reported. METHODS: This retrospective observational multicenter study aimed to describe efficacy and safety of ustekinumab in secukinumab nonresponder patients. RESULTS: A total of 21 patients unresponsive to secukinumab were treated with ustekinumab for a mean period of 53.3 weeks. Ustekinumab was effective in reducing disease severity, with significant improvements of both psoriasis area severity index (PASI) and dermatology quality of life index (DLQI) scores. PASI score improvements of 31.8, 44, 77.8, 80.3, 80.5, and 89.6%, at week 4, 12, 24, 36, 48, and above 60 weeks, respectively, were detected (p < 0.05), achieving PASI 50, 75, and > 90 responses in 93.8, 87.5, and 50% of patients at week 48. Four patients withdrew from ustekinumab treatment because of inefficacy, and failure of multiple biologic agents (> 2) seemed to affect ustekinumab drug survival. No serious adverse events (AEs) were reported while 38.1% of patients experienced mild AEs. CONCLUSION: Ustekinumab was safe and effective in treating patients unresponsive to secukinumab.

Published
2019

43. Secukinumab Drug Survival in Patients with Psoriasis: A multicenter, real-world, retrospective study

Author

Torres, Tiago, Balato, Anna, Conrad, Curdin, Conti, Andrea, Dapavo, Paolo, Ferreira, Paulo, Gaiani, Francesca, Leite, Luíz, Malagoli, Piergiorgio, Mendes-Basto, Pedro, Megna, Matteo, Messina, Francesco, Nidegger, Alessia, Odorici, Giulia, Piaserico, Stefano, Prignano, Francesca, Ribero, Simone, Ricceri, Federica, Tonini, Annalisa, Msc, Joana Valério, Chiricozzi, Andrea, Chiricozzi, Andrea (ORCID:0000-0002-6739-0387), Torres, Tiago, Balato, Anna, Conrad, Curdin, Conti, Andrea, Dapavo, Paolo, Ferreira, Paulo, Gaiani, Francesca, Leite, Luíz, Malagoli, Piergiorgio, Mendes-Basto, Pedro, Megna, Matteo, Messina, Francesco, Nidegger, Alessia, Odorici, Giulia, Piaserico, Stefano, Prignano, Francesca, Ribero, Simone, Ricceri, Federica, Tonini, Annalisa, Msc, Joana Valério, Chiricozzi, Andrea, and Chiricozzi, Andrea (ORCID:0000-0002-6739-0387)

Abstract

N/A

Published
2019

45. Secukinumab demonstrates improvements in absolute and relative psoriasis area severity indices in moderate-to-severe plaque psoriasis: results from a European, multicentric, retrospective, real-world study

Author

Chiricozzi, Andrea, primary, Balato, Anna, additional, Conrad, Curdin, additional, Conti, Andrea, additional, Dapavo, Paolo, additional, Ferreira, Paulo, additional, Gaiani, Francesca Maria, additional, Leite, Luiz, additional, Malagoli, Piergiorgio, additional, Mendes-Bastos, Pedro, additional, Megna, Matteo, additional, Messina, Francesco, additional, Nidegger, Alessia, additional, Odorici, Giulia, additional, Panduri, Salvatore, additional, Piaserico, Stefano, additional, Piscitelli, Leonardo, additional, Prignano, Francesca, additional, Ribero, Simone, additional, Valerio, Joana, additional, and Torres, Tiago, additional

Published
2019
Full Text
View/download PDF

46. Secukinumab drug survival in patients with psoriasis: A multicenter, real-world, retrospective study

Author

Torres, Tiago, primary, Balato, Anna, additional, Conrad, Curdin, additional, Conti, Andrea, additional, Dapavo, Paolo, additional, Ferreira, Paulo, additional, Gaiani, Francesca, additional, Leite, Luíz, additional, Malagoli, Piergiorgio, additional, Mendes-Bastos, Pedro, additional, Megna, Matteo, additional, Messina, Francesco, additional, Nidegger, Alessia, additional, Odorici, Giulia, additional, Piaserico, Stefano, additional, Prignano, Francesca, additional, Ribero, Simone, additional, Ricceri, Federica, additional, Tonini, Annalisa, additional, Valério, Joana, additional, and Chiricozzi, Andrea, additional

Published
2019
Full Text
View/download PDF

50. Phototherapy: The patients' point of view.

Author

Odorici, Giulia, Di Nuzzo, Sergio, Corazza, Monica, Bardazzi, Federico, Cortelazzi, Chiara, Sacchelli, Lidia, and Conti, Andrea

Subjects
*PHOTOTHERAPY, *PATIENT satisfaction, *TEMPERATE climate
Abstract

The average rating that patients assigned to the phototherapy service was 8.6/10, while 154 patients (46%) would have appreciated the chance to receive phototherapy at home (Table 1). This study highlights the point of view of patients undergoing phototherapy: Most of the patients in the study live within easy reach of the phototherapy center and have their own transport. Keywords: phototherapy; psoriasis; survey EN phototherapy psoriasis survey 175 179 5 03/22/21 20210301 NES 210301 Psoriasis is a chronic, relapsing, inflammatory disease affecting 2%-3% of the population. [Extracted from the article]

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results